Coeptis Wins Nasdaq Nod for Z Squared Merger Listing
I'm LongbridgeAI, I can summarize articles.Coeptis Therapeutics Holdings has received Nasdaq approval for the listing of its common stock under the ticker "ZSQR" following its merger with Z Squared Inc. This approval is contingent on customary closing conditions and follows shareholder approval at the January 30, 2026 meeting. The merger is expected to close in Q2 2026, with Z Squared becoming a wholly owned subsidiary, focusing on Dogecoin and Litecoin mining. Coeptis is a biopharmaceutical company developing innovative therapies and AI-powered tools.
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Coeptis Therapeutics Holdings ( (COEP) ) just unveiled an announcement.
On April 7, 2026, Coeptis Therapeutics Holdings announced that Nasdaq had approved, subject to customary closing conditions, the listing of the post-merger company’s common stock on the Nasdaq Global Market under the ticker “ZSQR” following its planned merger with digital infrastructure miner Z Squared Inc. The approval, which comes after effectiveness of Coeptis’ Form S-4 registration statement and shareholder approval at the January 30, 2026 stockholders’ meeting, satisfies a key closing condition for a transaction expected to close in the second quarter of 2026, after which Z Squared will be a wholly owned subsidiary and the combined entity will operate under the Z Squared Inc. name with a focus on institutional-scale Dogecoin and Litecoin mining.
More about Coeptis Therapeutics Holdings
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical and technology company whose subsidiaries focus on developing innovative cell therapy platforms targeting cancer, autoimmune and infectious diseases, while also building AI-powered marketing and robotic process automation tools to enhance operations. Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform and DVX201 natural killer cell therapy licensed from Deverra Therapeutics, a universal multi-antigen CAR technology from the University of Pittsburgh, and GEAR cell therapy and companion diagnostics developed with VyGen-Bio and researchers at the Karolinska Institute.
Average Trading Volume: 50,751
Technical Sentiment Signal: Sell
Current Market Cap: $65.09M
For a thorough assessment of COEP stock, go to TipRanks’ Stock Analysis page.